Version history

{
  "session_id": "sess_db9a224d-3ebb-429c-8f02-b703d71ca211_task_66f1207e_recon",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "scidex.core.llm.complete",
  "action": "assess",
  "content": "Domain expert assessment for analysis db9a224d-3ebb-429c-8f02-b703d71ca211: Non-Neuronal Transcriptional Changes Preceding Tau Propagation as Early AD Biomarkers\n\nThe practical path is feasible but should be staged. Stage 1 should reanalyze or collect human data at the needed resolution, preserving pathology, sex/genotype, region, and disease-stage covariates when relevant. Stage 2 should test APOE ε4-driven microglial lipid handling in a model where the proximal readout can be measured before overt toxicity. Stage 3 should connect the readout to a translational biomarker or intervention point.\n\nFor model systems, prioritize human iPSC-derived disease-relevant cells, co-culture or organoid systems only when the question explicitly requires cross-cell interaction, and mouse models only for organism-level timing or NMJ/vascular phenotypes. Biomarkers should be proximal to mechanism: transcriptional module activity, protein localization, lipid or RNA-modification state, spatial vascular coupling, or motor-unit integrity depending on the gap.\n\nThe development risk is moderate. The question is specific enough to generate falsifiable work, and it is anchored to Single-cell spatial transcriptomics reveals distinct patterns of dysregulation in non-neuronal cell types in Alzheimer's disease. The risk is that therapeutic tractability may lag mechanistic clarity: even if APOE ε4-driven microglial lipid handling is causal, the safest intervention point may be an upstream regulator, a cell-state transition, or a biomarker-guided patient subset rather than the named entity itself.",
  "tokens_used": "398",
  "persona_id": "persona-domain_expert"
}